Urinary biomarkers for prostate cancer: A review

Asian Journal of Andrology

Volumn 15, Issue 3, 2013, Pages 333-339

  Hessels, Daphne ^a   Schalken, Jack A ^b  

^a NovioGendix   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarkers; Diagnosis; Prostate cancer (PCa); Urinary biomarkers; Urine

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; APC PROTEIN; BIOLOGICAL MARKER; GLUTATHIONE TRANSFERASE P1; GOLGI PHOSPHOPROTEIN 2; MICRORNA; PROSTATE SPECIFIC ANTIGEN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; SERINE PROTEINASE INHIBITOR; TRANSMEMBRANE SERINE PROTEASE; UNCLASSIFIED DRUG;

DIAGNOSTIC ACCURACY; DISEASE MARKER; EPIGENETICS; EXOSOME; NON INVASIVE PROCEDURE; PROSTATE CANCER; PROTEIN URINE LEVEL; REVIEW; URINALYSIS;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; EXOSOMES; GENE EXPRESSION; GLUTAMATE CARBOXYPEPTIDASE II; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MICRORNAS; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES; RECEPTORS, RETINOIC ACID; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84877271000     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2013.6     Document Type: Review

References (85)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-81.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
3. Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005; 48: 386-99; discussion 98-9.
4. Li S, Hursting SD, Davis BJ, McLachlan JA, Barrett JC. Environmental exposure, DNA methylation, and gene regulation: lessons from diethylstilbesterol-induced cancers. Ann N Y Acad Sci 2003; 983: 161-9.
5. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-28.
6. Goessl C, Krause H, Muller M, Heicappell R, Schrader M et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 2000; 60: 5941-5.
7. Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA et al. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) Cp G island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: A detailed study using laser-capture microdissection. Am J Pathol 2003; 163: 923-33.
8. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A 1994; 91: 11733-7.
9. Goessl C, Muller M, Heicappell R, Krause H, Straub B et al. DNA-based detection of prostate cancer in urine after prostatic massage. Urology 2001; 58: 335-8.
10. Woodson K, O'Reilly KJ, Hanson JC, Nelson D, Walk EL et al. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J Urol 2008; 179: 508-11; discussion 11-2.
11. Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin Cancer Res 2003; 9: 2673-7.
12. Dammann R, Schagdarsurengin U, Strunnikova M, Rastetter M, Seidel C et al. Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. Histol Histopathol 2003; 18: 665-77.
13. Gordon M, El-Kalla M, Baksh S. RASSF1 polymorphisms in cancer. Mol Biol Int 2012; 2012: 365213.
14. Liu L, Yoon JH, Dammann R, Pfeifer GP. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene 2002; 21: 6835-40.
15. Kuzmin I, Gillespie JW, Protopopov A, Geil L, Dreijerink K et al. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res 2002; 62: 3498-502.
16. Aitchison A, Warren A, Neal D, Rabbitts P. RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues. Prostate 2007; 67: 638-44.
17. Kawamoto K, Okino ST, Place RF, Urakami S, Hirata H et al. Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Clin Cancer Res 2007; 13: 2541-8.
18. Roupret M, Hupertan V, Yates DR, Catto JW, Rehman I et al. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res 2007; 13: 1720-5.
19. Daniunaite K, Berezniakovas A, Jankevicius F, Laurinavicius A, Lazutka JR et al. Frequent methylation of RASSF1 and RARB in urine sediments from patients with early stage prostate cancer. Medicina (Kaunas) 2011; 47: 147-53.
20. Kwabi-Addo B, Chung W, Shen L, Ittmann M, Wheeler T et al. Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res 2007; 13: 3796-802.
21. Vener T, Derecho C, Baden J, Wang H, Rajpurohit Y et al. Development of a multiplexed urine assay for prostate cancer diagnosis. Clin Chem 2008; 54: 874-82.
22. Payne SR, Serth J, Schostak M, Kamradt J, Strauss A et al. DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection. Prostate 2009; 69: 1257-69.
23. Kumar-Sinha C, Rhodes DR, Yu J, Chinnaiyan AM. Prostate cancer biomarkers: A current perspective. Expert Rev Mol Diagn 2003; 3: 459-70.
24. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF et al. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975-9.
25. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002; 62: 2695-8.
26. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44: 8-15; discussion -6.
27. Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 2009; 6: 255-61.
28. Vlaeminck-Guillem V, Ruffion A, Andre J, Devonec M, Paparel P. Urinary prostate cancer 3 test: toward the age of reason? Urology 2010; 75: 447-53.
29. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006; 52: 1089-95.
30. Deras IL, Aubin SM, Blase A, Day JR, Koo S et al. PCA3: A molecular urine assay for predicting prostate biopsy outcome. J Urol 2008; 179: 1587-92.
31. Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol 2009; 56: 659-67.
32. Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ et al. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol 2010; 183: 534-8.
33. van Gils MP, Hessels D, van Hooij O, Jannink SA, Peelen WP et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a dutch multicenter validation of the diagnostic performance. Clin Cancer Res 2007; 13: 939-43.
34. Hessels D, van Gils MP, van Hooij O, Jannink SA, Witjes JA et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010; 70: 10-6.
35. van Gils MP, Hessels D, Hulsbergen-van de Kaa CA, Witjes JA, Jansen CF et al. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 2008; 68: 1215-22.
36. Liss MA, Santos R, Osann K, Lau A, Ahlering TE et al. PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols. World J Urol 2011; 29: 683-8.
37. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007; 69: 532-5.
38. Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008; 179: 1804-9; discussion 9-10.
39. Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 2008; 180: 1975-8; discussion 8-9.
40. Auprich M, Chun FK, Ward JF, Pummer K, Babaian R et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol 2011; 59: 96-105.
41. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Evidence of recurrent gene fusions in common epithelial tumors. Trends Mol Med 2006; 12: 529-36.
42. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-8.
43. Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005; 24: 3847-52.
44. Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006; 66: 3396-400.
45. Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 2008; 68: 73-80.
46. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB et al. Detection of TMPRSS2- ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007; 13: 5103-8.
47. Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS et al. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol; e-pub ahead of print 19 May 2011; doi: 10.1016/j.urolonc.2011.04.001.
48. Nguyen PN, Violette P, Chan S, Tanguay S, Kassouf Wet al. A panel of TMPRSS2:ERG fusion transcript markers for urine-based prostate cancer detection with high specificity and sensitivity. Eur Urol 2011; 59: 407-14.
49. Rostad K, Hellwinkel OJ, Haukaas SA, Halvorsen OJ, Oyan AM et al. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS 2009; 117: 575-82.
50. Demichelis F, Fall K, Perner S, Andren O, Schmidt F et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007; 26: 4596-9.
51. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 2011; 3: 94ra72.
52. Laxman B, Morris DS, Yu J, Siddiqui J, Cao J et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 2008; 68: 645-9.
53. Schmitz W, Albers C, Fingerhut R, Conzelmann E. Purification and characterization of an alpha-methylacyl-coa racemase from human liver. Eur J Biochem 1995; 231: 815-22.
54. Michaud DS, Augustsson K, Rimm EB, Stampfer MJ, Willet WC et al. A prospective study on intake of animal products and risk of prostate cancer. Cancer Causes Control 2001; 12: 557-67.
55. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL et al. Alpha-methylacyl-coa racemase: A new molecular marker for prostate cancer. Cancer Res 2002; 62: 2220-6.
56. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR et al. Alphamethylacyl coenzyme a racemase as a tissue biomarker for prostate cancer. JAMA 2002; 287: 1662-70.
57. Fleshman RL, Mac Lennan GT. Immunohistochemical markers in the diagnosis of prostate cancer. J Urol 2005; 173: 1759.
58. Jiang Z, Li C, Fischer A, Dresser K, Woda BA. Using an amacr (p504s)/34betae12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am J Clin Pathol 2005; 123: 231-6.
59. Jiang Z, Woda BA, Wu CL, Yang XJ. Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl coa racemase (p504s). Am J Clin Pathol 2004; 122: 275-89.
60. Kumar-Sinha C, Shah RB, Laxman B, Tomlins SA, Harwood J et al. Elevated alphamethylacyl- coa racemase enzymatic activity in prostate cancer. Am J Pathol 2004; 164: 787-93.
61. Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J et al. Humoral immune response to alpha-methylacyl-coa racemase and prostate cancer. J Natl Cancer Inst 2004; 96: 834-43.
62. Rogers CG, Yan G, Zha S, Gonzalgo ML, Isaacs WB et al. Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein. J Urol 2004; 172: 1501-3.
63. Zielie PJ, Mobley JA, Ebb RG, Jiang Z, Blute RD et al. A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl- coenzyme a racemase in prostatic secretions. J Urol 2004; 172: 1130-3.
64. Ouyang B, Bracken B, Burke B, Chung E, Liang J et al. A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-coa racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer. J Urol 2009; 181: 2508-13; discussion 13-4.
65. Burger MJ, Tebay MA, Keith PA, Samaratunga HM, Clements J et al. Expression analysis of delta-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer. Int J Cancer 2002; 100: 228-37.
66. Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003; 9: 6357-62.
67. Xiao Z, Adam BL, Cazares LH, Clements MA, Davis JW et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 2001; 61: 6029-33.
68. Zhang L, Wang CY, Yang R, Shi J, Fu R et al. Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis. Urol Oncol 2008; 26: 634-40.
69. Rigau M, Ortega I, Mir MC, Ballesteros C, Garcia M et al. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer. Prostate 2011; 71: 1736-45.
70. Elsasser-Beile U, Buhler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets 2009; 10: 118-25.
71. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ et al. Exosome-mediated transfer of mrnas and micrornas is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 654-9.
72. Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of micrornas and micrornaprotective protein by mammalian cells. Nucleic Acids Res 2010; 38: 7248-59.
73. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK et al. Circulating micrornas as stable blood-based markers for cancer detection. Proc Natl Acad Sci US A 2008; 105: 10513-8.
74. Yaman Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S et al. Investigation of mir-21, mir-141, and mir-221 in blood circulation of patients with prostate cancer. Tumour Biol 2011; 32: 583-8.
75. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL et al. Changes in circulating microrna levels associated with prostate cancer. Br J Cancer 2012; 106: 768-74.
76. Brase JC, Wuttig D, Kuner R, Sultmann H. Serum micrornas as non-invasive biomarkers for cancer. Mol Cancer 2010; 9: 306.
77. Kuner R, Brase JC, Sultmann H, Wuttig D. Microrna biomarkers in body fluids of prostate cancer patients. Methods 2013; 59: 132-7.
78. Gonzalez-Begne M, Lu B, Han X, Hagen FK, Hand AR et al. Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MUDPIT). J Proteome Res 2009; 8: 1304-14.
79. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008; 10: 1470-6.
80. Mathivanan S, Simpson RJ. Exocarta: A compendium of exosomal proteins and rna. Proteomics 2009; 9: 4997-5000.
81. Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microrna: A diagnostic marker for lung cancer. Clin Lung Cancer 2009; 10: 42-6.
82. Taylor DD, Gercel-Taylor C. Microrna signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008; 110: 13-21.
83. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ et al. Detection of microrna expression in human peripheral blood microvesicles. PLo S One 2008; 3: e3694.
84. Mitchell PJ, Welton J, Staffurth J, Court J, Mason MD et al. Can urinary exosomes act as treatment response markers in prostate cancer? J Transl Med 2009; 7: 4.
85. Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L et al. Prostate cancerderived urine exosomes: A novel approach to biomarkers for prostate cancer. Br J Cancer 2009; 100: 1603-7.